Ulcerative colitis (subacute manifestations) - infliximab (TA140)
Fast, easy summary view of NICE guidance on 'ulcerative colitis'
Infliximab is not recommended for people with subacute, moderately to severely active ulcerative colitis. Subacute ulcerative colitis is defined as ulcerative colitis that would normally be managed without needing to stay in hospital overnight or having urgent surgery.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: ulcerative colitis
- Ulcerative colitis (subacute manifestations) - infliximab: review decision - October 2012
- Ulcerative colitis (subacute manifestations) - infliximab: review proposal - August 2012
- Ulcerative colitis (subacute manifestations) - infliximab: review decision - June 2011
- Ulcerative colitis (subacute manifestations) - infliximab: review proposal - April 2011
- 2008/031 NICE appraisal of infliximab for ulcerative colitis
This page was last updated: 25 June 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA140 Infliximab ar gyfer llid briwiol y coluddyn lledlym - deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Audit support
- Costing report
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.